Hanimune Therapeutics

Hanimune has developed proprietary methods to modify the structure of allergenic food proteins so that they induce immune tolerance without triggering allergic reactions. The company has completed a seed round ($3.3M) to advance its lead program toward FDA review. Early results focus on prevention of food allergies in children using both direct protein modification therapies and consumer products for early allergen introduction.

The company also markets Lil Mixins, a consumer product line aimed at allergy prevention through early dietary exposure.

No published clinical trial results yet; programs are in preclinical or regulatory preparation stages.